News

Antibody mends a broken heart
Enlarge image

ResearchDenmarkSwitzerland

Antibody mends a broken heart

11.03.2013 - Genmab's antibody drug inclacumab significantly reduces damage to the heart muscle during angioplasty, Canadian researchers reported at the ACC Meeting.

In patients with acute coronary syndrome (ACS), who were treated by opening the blocked artery (Angioplasty/Percutaneous Coronary Intervention, PCI), Inclacumab (RO4905417, RG1512) helped significantly to lower the levels of  a biomarker clinically used to diagnose heart attacks. A single shot of the human anti-inflammatory antibody, which is co-developed by Genmab and Roche, reduced Troponin I levels by 24%, said Principal Investigator Dr. Jean-Claude Tardif from University of Montreal at the  international meeting of the American College of Cardiology (ACC) on 10 March.

"Inclacumab could indeed become an integral part of the therapeutic arsenal of modern cardiology if we can reproduce these results in subsequent studies", said the Director of the Research Centre at the Montreal Heart Institute. "We could use the drug for a broader patient population, or for all patients who present with a heart attack, but this will require further study." The human antibody targets P-selectin, a molecule which plays an important role in sending white blood cells to the site of an injury during inflammation.  

The Phase II trial conducted by Roche involved 530 patients with myocardial infarction who were randomised to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg, or placebo 1 to 24 hours before angioplasty. Markers for heart damage were then measured at 8, 16 and 24 hours after angioplasty.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/antibody-mends-a-broken-heart.html

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR15.48%
  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%

FLOP

  • MOLOGEN6.60 EUR-13.16%
  • WILEX2.15 EUR-1.83%
  • ADDEX3.40 CHF-1.16%

TOP

  • BIOFRONTERA2.92 EUR32.7%
  • BB BIOTECH157.00 EUR7.2%
  • ADDEX3.40 CHF6.6%

FLOP

  • PAION2.22 EUR-31.9%
  • CYTOS0.17 CHF-19.0%
  • MAGFORCE5.95 EUR-15.6%

TOP

  • SANTHERA84.30 CHF2248.2%
  • CO.DON2.84 EUR202.1%
  • PAION2.22 EUR161.2%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 22.10.2014